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VTE-related hospitalizations but the results were not statistically significant (odds
ratio: 0.857; 95% CI: 0.596-1.233). Sensitivity analysis results agreed with the pri-
mary findings (odds ratio: 0.831; 95% CI: 0.622-1.110). CONCLUSIONS: The risk of
hospitalization for VTE was found to be similar for users of typical and atypical
antipsychotic medication in this elderly Medicare population.
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TREATMENT PATTERNS, CLINICAL AND ECONOMIC BURDEN OF VENOUS
THROMBOEMBOLISM IN ABDOMINAL SURGERY PATIENTS
Wang L, Dysinger AH, Du J, Xie L, Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To examine prophylaxis use as it relates to the clinical and economic
burden of venous thromboembolism (VTE) in abdominal surgery patients.
METHODS: A retrospective study (January 1, 2005 to December 31, 2007) was con-
ducted using a subset of the MarketScan Hospital Drug Database and its linked
outpatient files from the Market Scan Commercial and Medicare Supplemental
database. Patients’ demographics, clinical and discharge statuses were compared
using Chi-square testing and standardized difference. Risk-adjusted healthcare
visits and costs were estimated using the General Linear Model. Potential risk
factors for VTE events were selected using the Cox Proportional Hazard Regression
Model. RESULTS: In patients who underwent abdominal surgery (n49,355),
24,473(49.59%) received anticoagulant therapy during their hospitalization and un-
til 30 days after discharge. VTE events for patients who received anticoagulant
prophylaxis were 4.63% versus 7.02% for patients who did not receive anticoagu-
lant prophylaxis. Compared with patients without VTE in the 6-month follow-up
period, patients with VTE were more likely to be older, have comorbid conditions
including previous VTE, major andminor bleeding, and cancer, and to have higher
baseline health care visits and costs. After risk adjustment for pre-specified cova-
riates, inpatient costs ($16,677 vs. $10,774), outpatient costs ($15,426 vs. $7,424),
pharmacy costs ($2,541 vs. $1,862), and readmission rates (0.23% vs. 0.12%) were
higher in patients who had VTE. In the multivariate analysis, appropriate antico-
agulant prophylaxis use was significantly associated with the reduced risk of VTE
(HR: 0.515).CONCLUSIONS:TheVTE event ratewas lower for patientswho received
prophylaxis compared with those who did not. Since the health care costs of pa-
tients with an event were significantly higher than those of patients without an
event, prophylaxis use is associated with lower health care costs.
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Critical limb ischemia (CLI) is a severe obstruction of the arteries that seriously
decreases blood flow to the extremities resulting in amputation of the affected limb
if left untreated. Despite the severity of the disease, there is a lack of data on
prevalence, incidence and outcomes of CLI in the United States. OBJECTIVES: We
conducted a large population-based study to directly estimate prevalence, inci-
dence and outcomes of CLI in theUnited States.METHODS:Data from January 2006
to December 2008 were extracted from the U.S. Medicare dataset. We estimated 1)
age, gender, race and diabetes-specific CLI prevalence and incidence rates using
the direct standardization method, and 2) factors associated with occurrence of
outcomes (leg revascularization, non-traumatic amputation, andmortality) among
the CLI population, using the Cox proportional hazard regressionmodel. RESULTS:
A total of 68,074 patients were identified with eligible CLI ICD-9 codes in 2007 of
whom 44.53% were diabetic. Analyzing 2 years of data, CLI prevalence and annual
incidence rates in this elderly population were 0.23% (0.28% for male and 0.20% for
female patients) and 0.20% (0.23% and 0.17%), respectively. Just as with prevalence,
incidence increased sharply among beneficiaries aged 65-69 (0.13%) to85 (0.31%),
was around 2.3 times higher in black patients compared to white patients, and 8.6
times higher in diabetic patients compared to non-diabetic patients. The overall
incidence rates of leg revascularization and non-traumatic amputation in the year
after CLI diagnosis were 29.7% and 25.2%, respectively. Compared to revasculariza-
tion, patients who are older, male, black, and have diabetes had a higher probabil-
ity of amputation. 30.3% of the patients died within the first year after CLI
diagnosis. CONCLUSIONS: This first U.S. nationwide-based study shows that prev-
alence, incidence and outcomes are different according to patients’ socio-demo-
graphic characteristics and comorbidities, suggesting that CLI patient manage-
ment varies among the U.S. population.
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OBJECTIVES: To estimate clinical outcomes, healthcare utilization and cost burden
of patients who suffered a myocardial infarction during the 180 days after diagno-
sis of non-valvular atrial fibrillation (NVAF) and compare it with patients who did
not suffer a myocardial infarction. METHODS: Based on 2005-2007 U.S. Medicare
advantage insurance claim files, patients aged 65 years and older who have had
two or more primary diagnoses for NVAF occurring within 30 days of one another
were selected. The 180-day follow-up event rates, healthcare facility use and costs
for patients with a myocardial infarction and those without were compared. Risk
adjustment was performed using the propensity score matching method with the
ProbChoice™ algorithm. RESULTS: In patients who were identified with NVAF
(n18,575), 258 (1.39%) suffered a myocardial infarction during the 180 days after
NVAFdiagnosis. Patientswere not significantly different in terms of gender, region,
and baseline comorbid conditions. After risk-adjustment for pre-specified covari-
ates, mortality (10.08% vs. 0.39% p0.0001), outpatient emergency room (ER) visits
(82.56% vs. 48.06% p0.0001), acute coronary syndrome (63 vs. 2/100 person years),
ischemic stroke (31 vs. 4/100 person years), major bleeding (10 vs. 1/100 person
years) and non-major clinical relevant bleeding (24 vs. 6/100 person years) were all
higher for patients who suffered a myocardial infarction compared to those who
did not. Besides inpatient costs ($26,646 vs. $9,393), risk-adjusted outpatient ER
costs ($1,176 vs. $863) were also higher for myocardial infarction patients. The
overall risk-adjusted difference in health care costs is significant ($36,584 vs.
$10,366 p0.0001). CONCLUSIONS: Most of the adverse events analyzed were
higher for patients who suffered a myocardial infarction after NVAF relative to
patients who did not. Total health care utilization and costs were also significantly
increased.
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OBJECTIVES: To examine the prophylaxis use, incidence of VTE, major bleeding,
minor bleeding and associated economic burden over 90 days in hospitalizedmed-
ically-ill patients. METHODS: A retrospective study (January 1, 2005 to December
31, 2007) was conducted using a subset of the MarketScan Hospital Drug Database
and its linked outpatient files from the Market Scan Commercial and Medicare
Supplemental database. Eligible patients were selected if they were continuously
enrolled in their health plan for at least 180 days prior to and 90 days following the
index hospital discharge date, which is hospitalization with amedically ill diagno-
sis. Prophylaxis use is defined as the admission date of index hospitalization to 30
days after index hospital discharge and before the date of their first VTE events.
Patients’ demographics, healthcare visits and costs were compared using Chi-
square testing and standardized differences. Risk-adjusted total healthcare costs
betweenpatientswith events andwithoutwere estimated using theGeneral Linear
Model. RESULTS: In patients who were identified as medically ill (n12,077),
6,464(53.52%) received anticoagulant therapy during their hospitalization and until
30 days after discharge. Compared with patients who did not receive any antico-
agulant prophylaxis, patients who received anticoagulant prophylaxis had signif-
icantly lower VTE events (1.47% vs. 3.58%, p0.0001). Although there was no sig-
nificant difference in rates of major bleeding and minor bleeding, after risk-
adjustment for pre-specified covariates, patients with outcome events were
significantly associatedwith higher total health care costs (VTE: $40,523 vs. $17,698
p0.0001; Major bleeding: $27,430 vs. $18,137 p0.0001; Minor bleeding: $25,696 vs.
$17,410 p0.0001). CONCLUSIONS: Despite existing guidelines, few medically-ill
patients are receiving anticoagulant prophylaxis. Appropriate anticoagulant pro-
phylaxis use results in lower VTE event rates and total follow-up health care costs
in hospitalized medically-ill patients.
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OBJECTIVES: Due to the reported higher incidences of adverse events in patients
on combination statins and fibrates compared to statins alone, the Veterans Affairs
(VA) San Diego initiated an intervention to reduce the number of patients on com-
bination therapies. This study aimed to evaluate the effectiveness and safety of
statin-fibrate combination therapies within the VA population. METHODS: This
was a retrospective cohort study of VA medical, pharmacy, and laboratory data.
Patients on a statin and fibrate combination in June 2008 were selected and strat-
ified based on continuation or discontinuation of combination therapy by June
2009. Hyperlipidemic measures, safety measures, and adverse events were ob-
tained pre- and post-intervention. Chi-square and ANOVA tests were utilized to
test between-group differences and paired t-tests were conducted to analyze with-
in-group differences at pre- and post-intervention. Repeatedmeasures regressions
were used to assess longitudinal differences between groups over time. RESULTS:
No differences in rates of cardiovascular diseasewere found between patients who
continued and discontinued combination therapy at baseline and one year later.
No incidences of rhabdomyolysis and pancreatitis were reported. Compared to
those who continued combination therapy, those who discontinued combination
therapy had significantly lower total cholesterol (184 versus 172 mg/dL, p0.029),
higher CK (171 versus 132 U/L, p0.006), and lower triglyceride levels post-inter-
vention. There were no significant longitudinal differences between groups over
time. Within the patients who discontinued combination therapy, AST and ALT
were significantly lower after the intervention while total cholesterol and LDL lev-
els were higher post-intervention. Within those who continued, ALT was lower
while total cholesterol, LDL, andCKwere higher post-intervention.CONCLUSIONS:
Discontinuation of statin-fibrate combination therapy did not have a significant
impact on the management of hyperlipidemia measures and no differences in
adverse events were observed. Further studies should be done to assess the long-
term effects of statin-fibrate combination therapy.
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